The identification of specific gene mutations, such as MAP2K4, FGFR3, APC, KIT, RB1, and PTEN, which are linked to higher relapse risks and show a trend toward significance in the large METABRIC cohort, underscores the importance of further research before these genetic markers can be used to enhance patient stratification and personalized treatment strategies.
← all excerpts
Select gene mutations associated with survival outcomes in ER-positive ERBB2-negative early-stage invasive breast cancer: A single-institutional tissue bank study.
1
—
—